Report cover image

Latin America Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Onli

Publisher Allied Market Research
Published May 02, 2023
Length 79 Pages
SKU # ALMR18790557

Description

Latin America Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Opportunity Analysis and Industry Forecast, 2023-2032


Latin America myasthenia gravis treatment market is projected to register a CAGR of over 5.71% during the forecast period. Myasthenia gravis is an autoimmune disorder that causes muscle mass weakness. People dealing with myasthenia gravis experience dual vision, sagging eyelids, slurred speech, and difficulty in swallowing. The therapy for myasthenia gravis revolves around immunosuppressive drugs, cholinergic medicines, and restorative therapies.

The Latin America myasthenia gravis treatment market is driven by rise in the occurrence of myasthenia gravis, which increases the demand for its treatment. In addition, increase in awareness regarding the severity of the illness and availability of different therapies has boosted the demand for myasthenia gravis treatment in the market. In addition, R&D in the field of therapies such as thymectomy, T-cell inoculation, and immunomodulatory approaches is expected to boost the market growth. Furthermore, rise in demand for minimally invasive diagnostic strategies for large-scale patient profiling and increase in investments in creating targeted therapies are anticipated to intensify the market development. However, the Latin America myasthenia gravis treatment market is challenged by several restraints. The major restraints for the growth of the Latin America myasthenia gravis treatment market are high cost of treatment and side effects from medication & treatment.

On the other hand, the development of analytical methods to assess the effect of numerous therapies along with therapy programs on myasthenia gravis patients has paved the way for potential opportunities for the market growth in the coming years. The usage of innovative strategies, such as model-based drug development (MBDD) to examine the effectiveness of treatments is expected to boost the concept of individualized medicine. Further, the presence of e-health systems such as patient-specific condition modeling platforms is expected to play a substantial role in improving the disease treatment process. Using the data sourced from e-health systems, clinicians are anticipated to create unique therapies for myasthenia gravis. In addition, the development of wearable sensors and mobile apps is anticipated to make it possible for diagnosis and tailored therapies for myasthenia gravis clients.

The Latin America myasthenia gravis treatment market is expected to break brand-new ground, owing to the emergence of innovative treatments for myasthenia gravis. As R&D activities in this field remain to stream forward, immunomodulatory approaches like Thymectomy and T-cell Vaccination are anticipated to bundle a new collection of possibilities for the market. In addition, current developments in genetic treatment are expected to lead the way for the future of myasthenia gravis therapy. Using gene-based ingredients, such as Myostatin Gene treatment, is expected to transform the present therapy landscape and also open potential opportunities for the market to discover in the future.

Moreover, the introduction of machine learning and artificial intelligence applications for medicine design and advancement is expected to outfit clinicians with improved degrees of technological insights. Based on medication class, the Latin America myasthenia gravis treatment market is segmented right into Monoclonal antibodies, Intravenous Immunoglobulin, and Others. Monoclonal antibodies have a significant market share in the marketplace as they are target-specific as well as act as disease-modifying medications. Based on age, the market is bifurcated into below 55 years and above 55 years. Based on the distribution channel, the market is segmented right into Health center Pharmacies, Medication shop as well as Retail Pharmacies, as well as Online Providers.

Key Benefits for Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in the Latin America myasthenia gravis treatment market.

Assess and rank the top factors that are expected to affect the growth of the Latin America myasthenia gravis treatment market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Latin America myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Age group

Below 55 years
Above 55 years

By Drug class

Monoclonal antibodies
Intravenous immunoglobulin
Others

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

Key Market Players

GlaxoSmithKline plc.
Pfizer, Inc.
Johnson & Johnson
Novartis AG
Sanofi
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Biogen Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

79 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
CHAPTER 5: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
CHAPTER 6: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. GlaxoSmithKline plc.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Pfizer, Inc.
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Johnson & Johnson
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Novartis AG
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Sanofi
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. F. Hoffmann-La Roche Ltd.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. AbbVie Inc.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Mylan N.V.
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Biogen Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 05. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 06. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 07. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 08. GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 09. PFIZER, INC.: KEY EXECUTIVES
TABLE 10. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 11. PFIZER, INC.: OPERATING SEGMENTS
TABLE 12. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 13. PFIZER, INC.: KEY STRATERGIES
TABLE 14. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 15. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 16. JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 17. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 18. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 19. NOVARTIS AG: KEY EXECUTIVES
TABLE 20. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 21. NOVARTIS AG: OPERATING SEGMENTS
TABLE 22. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 23. NOVARTIS AG: KEY STRATERGIES
TABLE 24. SANOFI: KEY EXECUTIVES
TABLE 25. SANOFI: COMPANY SNAPSHOT
TABLE 26. SANOFI: OPERATING SEGMENTS
TABLE 27. SANOFI: PRODUCT PORTFOLIO
TABLE 28. SANOFI: KEY STRATERGIES
TABLE 29. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 30. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 31. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 32. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 33. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 34. ABBVIE INC.: KEY EXECUTIVES
TABLE 35. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 36. ABBVIE INC.: OPERATING SEGMENTS
TABLE 37. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 38. ABBVIE INC.: KEY STRATERGIES
TABLE 39. MYLAN N.V.: KEY EXECUTIVES
TABLE 40. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 41. MYLAN N.V.: OPERATING SEGMENTS
TABLE 42. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 43. MYLAN N.V.: KEY STRATERGIES
TABLE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 49. BIOGEN INC.: KEY EXECUTIVES
TABLE 50. BIOGEN INC.: COMPANY SNAPSHOT
TABLE 51. BIOGEN INC.: OPERATING SEGMENTS
TABLE 52. BIOGEN INC.: PRODUCT PORTFOLIO
TABLE 53. BIOGEN INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. PFIZER, INC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. PFIZER, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. JOHNSON & JOHNSON: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. JOHNSON & JOHNSON: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. JOHNSON & JOHNSON: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. NOVARTIS AG: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. SANOFI: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. SANOFI: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. SANOFI: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. ABBVIE INC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. ABBVIE INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. MYLAN N.V.: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. MYLAN N.V.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. BIOGEN INC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. BIOGEN INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us